If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Carmela Pisano is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 30 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Platinum Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
trabectedin Medicine & Life Sciences
Carboplatin Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

  • 1498 Citations
  • 21 h-Index
  • 80 Article
  • 2 Review article
  • 1 Chapter

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G. & Scambia, G., Jan 1 2019, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Carboplatin
Endometrial Neoplasms
Paclitaxel
Disease-Free Survival
Combination Drug Therapy

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

on behalf of the AGO Study Group-led GCIG/ENGOT Intergroup Consortium, Jan 1 2019, (Accepted/In press) In : International Journal of Cancer.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Placebos
Drug Therapy
Survival
Gynecology

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

Daniele, G., Arenare, L., Scambia, G., Pisano, C., Sorio, R., Breda, E., De Placido, S., Savarese, A., Ferrandina, G., Raspagliesi, F., Panici, P. B., Ferro, A., Rimanti, A., Cormio, G., Lorusso, D., Cecere, S. C., Scalone, S., Marsico, V. A., Cardalesi, C., Cognetti, F. & 8 others, Salutari, V., Attademo, L., Guizzaro, L., Schettino, C., Piccirillo, M. C., Perrone, F., Gallo, C. & Pignata, S., 2019, In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Neutropenia
Ovarian Neoplasms
Drug Therapy
Neoplasms
Therapeutics
Carboplatin
Paclitaxel
Uterine Cervical Neoplasms
Disease-Free Survival
Epidermal Growth Factor Receptor

Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study

Mangili, G., Cioffi, R., Danese, S., Frigerio, L., Ferrandina, G., Cormio, G., Rabaiotti, E., Scarfone, G., Gadducci, A., Bergamini, A. & Pisano, C., 2018, In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Gestational Trophoblastic Disease
Methotrexate
Therapeutics
Leucovorin
Multicenter Studies